Login to Your Account



Clinic Roundup


Wednesday, April 13, 2011
Durect Corp., of Cupertino, Calif., said top-line results from a Phase II trial showed that Eladur (Transdur-Bupivacaine), its transdermal bupivacaine pain patch, missed the primary endpoint of demonstrating a positive treatment difference over placebo for the mean change in pain intensity scores from baseline to the mean of week 11 and week 12. Complete data analysis is ongoing.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription